Pub Date : 2023-07-25DOI: 10.14716/ijtech.v14i5.5966
Brian Pamukti, Amirullah Wijayanto, S. Liaw
{"title":"High-Bit-Rate Transmission in Visible Light Communication System Based on Adaptive Successive Interference Cancellation Technique","authors":"Brian Pamukti, Amirullah Wijayanto, S. Liaw","doi":"10.14716/ijtech.v14i5.5966","DOIUrl":"https://doi.org/10.14716/ijtech.v14i5.5966","url":null,"abstract":"","PeriodicalId":50285,"journal":{"name":"International Journal of Technology Management","volume":"463 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76467954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"管理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-25eCollection Date: 2024-04-01DOI: 10.1159/000531744
Ciro Celsa, Giuseppe Cabibbo, David James Pinato, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Paolo Giuffrida, Carmelo Marco Giacchetto, Gabriele Rancatore, Maria Vittoria Grassini, Calogero Cammà
Background: Atezolizumab + bevacizumab represent the current standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, direct comparison with other combination treatments including immune checkpoint inhibitors (ICI) + tyrosine kinase inhibitors (TKIs) are lacking.
Objectives: This network meta-analysis (NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable advanced HCC.
Method: A literature search of MEDLINE, Embase, and SCOPUS databases was conducted up to October 31, 2022. Phase 3 randomized controlled trials (RCTs) testing TKIs, including sorafenib and lenvatinib, or ICIs reporting overall survival (OS) and progression-free survival (PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time. A Bayesian NMA was performed to compare treatments in terms of efficacy (15- and 30-month OS, 6-month PFS) and safety, represented by grade ≥3 (severe) adverse events (SAEs). The incremental safety-effectiveness ratio as measure of net health benefit was calculated as the difference in SAE probability divided by survival difference between the 2 most effective treatments.
Results: Nine RCTs enrolling 6,600 patients were included. Atezolizumab plus bevacizumab showed the highest probability (88%) of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus bevacizumab showed the best net health benefit for OS, compared to durvalumab plus tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, atezolizumab plus bevacizumab was favoured in 78% of cases, while at threshold of 30% of SAEs for life-month gained, lenvatinib was favoured in 76% of cases.
Conclusions: Atezolizumab plus bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to atezolizumab plus bevacizumab, lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
{"title":"Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.","authors":"Ciro Celsa, Giuseppe Cabibbo, David James Pinato, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Paolo Giuffrida, Carmelo Marco Giacchetto, Gabriele Rancatore, Maria Vittoria Grassini, Calogero Cammà","doi":"10.1159/000531744","DOIUrl":"10.1159/000531744","url":null,"abstract":"<p><strong>Background: </strong>Atezolizumab + bevacizumab represent the current standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, direct comparison with other combination treatments including immune checkpoint inhibitors (ICI) + tyrosine kinase inhibitors (TKIs) are lacking.</p><p><strong>Objectives: </strong>This network meta-analysis (NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable advanced HCC.</p><p><strong>Method: </strong>A literature search of MEDLINE, Embase, and SCOPUS databases was conducted up to October 31, 2022. Phase 3 randomized controlled trials (RCTs) testing TKIs, including sorafenib and lenvatinib, or ICIs reporting overall survival (OS) and progression-free survival (PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time. A Bayesian NMA was performed to compare treatments in terms of efficacy (15- and 30-month OS, 6-month PFS) and safety, represented by grade ≥3 (severe) adverse events (SAEs). The incremental safety-effectiveness ratio as measure of net health benefit was calculated as the difference in SAE probability divided by survival difference between the 2 most effective treatments.</p><p><strong>Results: </strong>Nine RCTs enrolling 6,600 patients were included. Atezolizumab plus bevacizumab showed the highest probability (88%) of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus bevacizumab showed the best net health benefit for OS, compared to durvalumab plus tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, atezolizumab plus bevacizumab was favoured in 78% of cases, while at threshold of 30% of SAEs for life-month gained, lenvatinib was favoured in 76% of cases.</p><p><strong>Conclusions: </strong>Atezolizumab plus bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to atezolizumab plus bevacizumab, lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.</p>","PeriodicalId":50285,"journal":{"name":"International Journal of Technology Management","volume":"1 1","pages":"169-180"},"PeriodicalIF":13.8,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72548604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"管理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-25DOI: 10.14716/ijtech.v14i5.5272
H. Devianto, I. Nurdin, P. Widiatmoko, Della Silvia, Clarissa Prakarsa
{"title":"Tobacco Extract for Inhibition of Carbon Steel Corrosion in H2S-contained NaCl Solution","authors":"H. Devianto, I. Nurdin, P. Widiatmoko, Della Silvia, Clarissa Prakarsa","doi":"10.14716/ijtech.v14i5.5272","DOIUrl":"https://doi.org/10.14716/ijtech.v14i5.5272","url":null,"abstract":"","PeriodicalId":50285,"journal":{"name":"International Journal of Technology Management","volume":"270 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76754323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"管理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-25DOI: 10.14716/ijtech.v14i5.6032
Yahya M. Altharan, S. Shamsudin, Sami. Al-Alimi, Mohammed A. Jubair
{"title":"Development of Zirconia Reinforced AA7075/AA7050 Aluminum Chip-Based Composite Processed Using Hot Press Forging Method","authors":"Yahya M. Altharan, S. Shamsudin, Sami. Al-Alimi, Mohammed A. Jubair","doi":"10.14716/ijtech.v14i5.6032","DOIUrl":"https://doi.org/10.14716/ijtech.v14i5.6032","url":null,"abstract":"","PeriodicalId":50285,"journal":{"name":"International Journal of Technology Management","volume":"38 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84854383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"管理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-25DOI: 10.14716/ijtech.v14i5.5299
B. Prasetya, Yopi Yopi, B. Tampubolon
{"title":"Role of Risk Management and Standardization for supporting Innovation in New Normal based on Lessons Learned during Pandemic COVID-19","authors":"B. Prasetya, Yopi Yopi, B. Tampubolon","doi":"10.14716/ijtech.v14i5.5299","DOIUrl":"https://doi.org/10.14716/ijtech.v14i5.5299","url":null,"abstract":"","PeriodicalId":50285,"journal":{"name":"International Journal of Technology Management","volume":"34 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87321841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"管理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-25DOI: 10.14716/ijtech.v14i5.6149
M. A. Budiyanto, Sultan Alif Zidane, Gerry Liston Putra, Achmad Riadi, Riezqa Andika, G. Theotokatos
{"title":"Performance Analysis of Combined Gas-Electric Steam Turbine System as Main Propulsion for Small-scale LNG Carrier Ships","authors":"M. A. Budiyanto, Sultan Alif Zidane, Gerry Liston Putra, Achmad Riadi, Riezqa Andika, G. Theotokatos","doi":"10.14716/ijtech.v14i5.6149","DOIUrl":"https://doi.org/10.14716/ijtech.v14i5.6149","url":null,"abstract":"","PeriodicalId":50285,"journal":{"name":"International Journal of Technology Management","volume":"178 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85439841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"管理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-25DOI: 10.14716/ijtech.v14i5.6578
Y. Whulanza, E. Kusrini
{"title":"Defining Healthy City and Its Influence on Urban Well-being","authors":"Y. Whulanza, E. Kusrini","doi":"10.14716/ijtech.v14i5.6578","DOIUrl":"https://doi.org/10.14716/ijtech.v14i5.6578","url":null,"abstract":"","PeriodicalId":50285,"journal":{"name":"International Journal of Technology Management","volume":"34 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88026013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"管理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-25DOI: 10.14716/ijtech.v14i5.6370
S. Satriana, Amrina Maulida, Rizky Qardhawi, Y. M. Lubis, R. Moulana, W. Mustapha, N. Arpi
{"title":"Study of Solid–Liquid Extraction Kinetics of Oil from Dried Avocado (Persea Americana) Flesh Using Hexane as A Solvent","authors":"S. Satriana, Amrina Maulida, Rizky Qardhawi, Y. M. Lubis, R. Moulana, W. Mustapha, N. Arpi","doi":"10.14716/ijtech.v14i5.6370","DOIUrl":"https://doi.org/10.14716/ijtech.v14i5.6370","url":null,"abstract":"","PeriodicalId":50285,"journal":{"name":"International Journal of Technology Management","volume":"34 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73000064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"管理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}